ArticleJournal of exercise science and fitness2026
The impact of accelerometer-derived 'weekend warrior' physical activity on musculoskeletal disorders and multimorbidity development.
Article in Journal of exercise science and fitness, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whether concentrating moderate-to-vigorous physical activity (MVPA) into 1-2 days ("weekend warrior", WW) provides musculoskeletal benefits comparable to more evenly distributed weekly activity ("regular activity", RA) remains unclear. Methods: In a prospective UK Biobank accelerometer cohort (n = 52,606), participants free of musculoskeletal disease at baseline were classified hierarchically: inactive (<150 min/week MVPA); among those meeting the guideline threshold (≥150 min/week), WW (≥50% of weekly MVPA accrued within the most active 1-2 days) and RA (≥150 min/week but not meeting the WW criterion). Over a median 8.2 years of follow-up, there were 4107 osteoarthritis (OA), 2454 spine degenerative changes (SDCs), and 1006 osteoporosis (OP) events. Cox models estimated incident outcomes; multi-state models estimated transitions among baseline, first musculoskeletal disease, musculoskeletal multimorbidity (MSM), and death. Results: Compared with inactivity, both RA and WW were associated with lower risks of OA (RA hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.69-0.83; WW HR 0.83, 0.77-0.89; both p < 0.001), SDCs (RA HR 0.85, 0.76-0.95, p = 0.004; WW HR 0.85, 0.78-0.94, p = 0.001), and OP (RA HR 0.74, 0.62-0.88; WW HR 0.75, 0.65-0.87; both p < 0.001). In multi-state analyses, mortality was lower versus inactivity from baseline for both RA (HR 0.61, 0.55-0.69; p < 0.001) and WW (HR 0.59, 0.54-0.65; p < 0.001), with a stronger reduction after MSM for WW (HR 0.42, 0.25-0.72; p = 0.001) than RA (HR 0.83, 0.48-1.43; p = 0.502). Conclusion: Meeting MVPA recommendations via WW may provide comparable musculoskeletal risk reduction to RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.